- The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.
- Quest was awarded the contract following a competitive bid. The total contract value with all options is valued at up to approximately $19.5 million.
- The new agreement extends and broadens the scope of the company's contributions to the CDC's seroprevalence research.
- Also Read: Quest Diagnostics Q4 Earnings, FY22 Reflects Lower Demand For COVID-19 Testing Services.
- Quest to employ its comprehensive menu of COVID-19 antibody test and data analytics services to support population health research across 45 states and Puerto Rico.
- The company's serological tests are authorized by the FDA for emergency use and aid in identifying antibodies produced in response to recent or prior infection and/or vaccination.
- Quest will provide the data analysis to the CDC in a HIPAA-compliant manner to support public health analysis and reporting.
- Price Action: DGX shares closed 0.56% higher at $143.05 during after-hours trading on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Quest Diagnostics Secures CDC Contract To Support COVID-19 Research
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks